BRIEF-Manitex Capital’s affiliate, Valeo Pharma announces partnership for parkinson’s disease treatment – Reuters

Posted: Published on April 11th, 2017

This post was added by Alex Diaz-Granados

April 11 Manitex Capital Inc:

* Manitex Capital Inc's affiliate, Valeo Pharma Inc, announces partnership for a parkinson's disease treatment

* Manitex Capital- entered into partnership with Zambon s.p.a. For exclusive Canadian rights to commercialize new parkinson's disease product Xadago

* Manitex Capital Inc says valeo pharma will pay zambon upfront, regulatory and commercial milestone payments as well as royalties on product sales

* Manitex Capital - under terms of deal, Valeo Pharma to be responsible for all regulatory, sales, marketing, quality, distribution activities in Canada

* Manitex Capital - agreement grants Valeo Pharma exclusive rights to commercialise Zambon's parkinson's disease product, licensed from Newron Source text for Eikon: Further company coverage:

* Allies see Trump missile strikes as reversal of isolationism

April 11 Neel Kashkari, the chief of the Minneapolis Federal Reserve who was the lone dissenter on the Fed's rate hike last month, repeated Tuesday his view that there is still slack in the labor market and that inflation is still lower than it should be.

Link:
BRIEF-Manitex Capital's affiliate, Valeo Pharma announces partnership for parkinson's disease treatment - Reuters

Related Posts
This entry was posted in Parkinson's Treatment. Bookmark the permalink.

Comments are closed.